JUSTIN CLAY: Open Payments
NPI 1548669005 · CHARLESTON, WV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$679 in 45 payments from 12 companies in 2025. Trend: 2023 $2,099 · 2024 $2,263 · 2025 $679
Food & beverage: $679
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $224 |
| ABBVIE INC. | 11 | $141 |
| Dexcom, Inc. | 4 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 3 | $24 |
| ABIOMED | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
Products named: Ozempic, QULIPTA, Dexcom G6 Transmitter, CAPLYTA, Wegovy, XIFAXAN, Kerendia, VRAYLAR.
Industry payments across WV — which companies pay providers there.
